The pioneering p300/CBP drug development company
We are developing inobrodib, an oral, first-in-class small molecule inhibitor of p300/CBP, for the treatment of multiple myeloma and other cancers.
Inobrodib, an oral, first-in-class p300/CBP inhibitor
CellCentric is a clinical-stage biopharmaceutical company with a science-driven and patient-focused mission. Our drug inobrodib is a first-in-class p300/CBP inhibitor that is being developed for the treatment of multiple myeloma and other specific cancers. Our aim is to develop inobrodib as quickly and as effectively as possible for the benefit of patients.
About inobrodib
Inobrodib is a small molecule that disrupts the growth of cancer cells by inhibiting twin proteins p300 and CBP. These act as transcription co-activation factors of genes involved in tumor progression, including MYC and IRF4.
Inobrodib works by binding to the bromodomain of p300/CBP. It is a highly selective molecule and does not impact similar pockets on other proteins. Inobrodib displaces, rather than degrades, both p300 and CBP from super enhancer sites to other parts of chromatin, reducing the expression of certain cancer-driving genes. Inobrodib continues to be evaluated in clinical trials, where it is showing promise in multiple cancer types, particularly in multiple myeloma.
Patient focus
Many new cancer treatments, including those for multiple myeloma, are complex and require significant hospitalization time to administer. InoPd—inobrodib in combination with a standard backbone of care pomalidomide + dexamethasone (Pd)—is a new approach being developed for use in a community setting. We aim to reduce burden on the healthcare system, reach wider patient populations, ensuring greater access. A key preference of patients is to feel in control of their cancer treatment and oral treatments are part of that.
Inobrodib is also being evaluated in conjunction with other standard of care therapies.
